## First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer **Key Point:** Paclitaxel + Carboplatin (TC regimen) is the gold-standard first-line chemotherapy for advanced-stage epithelial ovarian cancer (stages III–IV). ### Mechanism & Rationale **Paclitaxel** — a taxane that stabilizes microtubules and induces apoptosis; shows superior response rates in ovarian cancer. **Carboplatin** — a platinum agent that forms DNA adducts; synergistic with paclitaxel and has a more favorable toxicity profile than cisplatin in this setting. ### Evidence Base The combination of paclitaxel + carboplatin became standard after landmark trials (GOG-111, ICON3) demonstrated: - Superior progression-free survival (PFS) and overall survival (OS) compared to older regimens. - Better tolerability than cisplatin-based combinations. - Response rates of 60–70% in advanced disease. ### Dosing & Schedule | Parameter | Standard Regimen | | --- | --- | | Paclitaxel | 175 mg/m² IV over 3 hours | | Carboplatin | AUC 5–6 IV | | Cycle length | Every 21 days | | Number of cycles | 6 cycles (standard) | **Clinical Pearl:** Bevacizumab (anti-VEGF monoclonal antibody) is often added to the TC backbone in front-line therapy for stage IV disease or recurrent ovarian cancer, improving PFS. However, the chemotherapy backbone remains paclitaxel + carboplatin. **High-Yield:** The TC regimen is also used for: - Recurrent platinum-sensitive ovarian cancer (re-challenge with TC if platinum-free interval > 6 months). - Borderline ovarian tumors (selected cases). **Tip:** Premedication with dexamethasone, diphenhydramine, and ranitidine is required before paclitaxel to prevent hypersensitivity reactions.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.